Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: a California Cancer Consortium Trial

PURPOSE: A phase I study was conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of fenretinide delivered as an intravenous emulsion in relapsed/refractory hematologic malignancies. EXPERIMENTAL DESIGN: Fenretinide (80 – 1810 mg/m(2)/day) was...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Mohrbacher, Ann M., Yang, Allen S., Groshen, Susan, Kummar, Shivaani, Gutierrez, Martin E., Kang, Min H., Tsao-Wei, Denice, Reynolds, C. Patrick, Newman, Edward M., Maurer, Barry J.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5559312/
https://ncbi.nlm.nih.gov/pubmed/28420721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0234
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars